Potential Sciences
Category: AI in Biotech / Drug Discovery
London-based AI drug-discovery startup building GPU-native quantum chemistry simulation for molecular modelling. Potential Sciences was founded in 2025. The company is led by Dr. Hatem Helal. Based in London, United Kingdom. Team size: 1-10. Latest round: Undisclosed. Key investors include Bluewire Capital, Odyssey Ventures, Rule30.
- Founded
- 2025
- Headquarters
- London, United Kingdom
- Team size
- 1-10
Value proposition
GPU-native quantum chemistry simulation that accelerates molecular modelling and drug discovery by combining high-fidelity electronic structure methods with machine learning.
Products and solutions
GPU-native quantum chemistry simulation engine for molecular modelling, scientific computing software supporting density functional theory (DFT) workflows and molecular property prediction.
Unique value
Combines deep expertise in quantum chemistry and ML with GPU-native simulation to deliver high-fidelity molecular modelling at scale — targeting the compute bottleneck in AI-driven drug discovery.
Target customer
Pharmaceutical and biotech R&D organizations; computational chemistry and materials modelling teams.
Industries served
AI in Biotech / Drug Discovery, Computational Chemistry, Life Sciences R&D
Technology advantage
GPU-native quantum chemistry simulation; founder's track record building large-scale quantum chemistry ML datasets (QM1B, 1B training examples) and graph neural network models for molecular property prediction at Graphcore.
How they differentiate
Focus on GPU-native quantum chemistry simulation (electronic structure) rather than broad generative drug design; leverages founder's specialized expertise in accelerating DFT/quantum chemistry on modern accelerators.
Main competitors
Isomorphic Labs, Schrödinger, Microsoft Azure Quantum Elements
Major milestones
Incorporated as Potential Sciences UK Ltd on 18 Nov 2025, reported (Sept 2026) to be in talks with the UK's £500M Sovereign AI Investment Fund to anchor a ~£500M raise — among the UK's largest AI raises this year.
Market positioning
Early-stage UK AI drug-discovery startup positioned in the high-value life-sciences AI segment; reportedly in talks for a £500M round that would place it among the UK's largest AI raises.
Geographic focus
United Kingdom / Europe; global pharma R&D market
About Dr. Hatem Helal
Ex-Research Scientist at Graphcore (GNNs for molecular simulation, QM1B dataset); Ex-Valence Labs / Recursion (quantum chemistry + ML); PhD-level physics/ML background. Founded Potential Sciences in 2025.
Latest news about Potential Sciences
More AI in Biotech / Drug Discovery companies
Official website: https://potentialsciences.com/